CATX - Perspective Therapeutics, Inc.

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 15.26

Open

Bid

$ 15.32 x 100

Ask

$ 15.36 x 100

Day's Range

-- - --

52 Week Range

$ 2.05 - $ 19.05

Volume

414,415

Average Volume

Market Cap

1.03B

Beta (5Y Monthly)

$ 0.74

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2024	06-30-2024	10-Q
2	05-15-2024	03-31-2024	10-Q
3	03-28-2024	12-31-2023	10-K
4	11-14-2023	09-30-2023	10-Q
5	08-11-2023	06-30-2023	10-Q
6	05-15-2023	03-31-2023	10-Q
7	11-14-2022	09-30-2022	10-Q
8	09-28-2022	06-30-2022	10-K
9	05-12-2022	03-31-2022	10-Q
10	02-09-2022	12-31-2021	10-Q
11	11-10-2021	09-30-2021	10-Q
12	09-27-2021	06-30-2021	10-K
13	05-14-2021	03-31-2021	10-Q
14	02-09-2021	12-31-2020	10-Q
15	11-13-2020	09-30-2020	10-Q
16	09-25-2020	06-30-2020	10-K
17	05-13-2020	03-31-2020	10-Q
18	02-12-2020	12-31-2019	10-Q
19	11-13-2019	09-30-2019	10-Q
20	09-27-2019	06-30-2019	10-K
21	05-10-2019	03-31-2019	10-Q
22	02-13-2019	12-31-2018	10-Q
23	11-09-2018	09-30-2018	10-Q
24	09-26-2018	06-30-2018	10-K
25	05-04-2018	03-31-2018	10-Q
26	02-09-2018	12-31-2017	10-Q
27	11-14-2017	09-30-2017	10-Q
28	09-28-2017	06-30-2017	10-K
29	05-10-2017	03-31-2017	10-Q
30	02-09-2017	12-31-2016	10-Q
31	11-09-2016	09-30-2016	10-Q
32	09-09-2016	06-30-2016	10-K
33	05-10-2016	03-31-2016	10-Q
34	02-09-2016	12-31-2015	10-Q
35	11-09-2015	09-30-2015	10-Q
36	09-14-2015	06-30-2015	10-K
37	05-15-2015	03-31-2015	10-Q
38	02-17-2015	12-31-2014	10-Q
39	11-14-2014	09-30-2014	10-Q
40	09-29-2014	06-30-2014	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cantor Fitzgerald Reiterates Overweight on...
09/06/2024 14:10:56

Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.

Perspective Therapeutics Says FDA Granted ...
09/05/2024 11:41:59

Cantor Fitzgerald Reiterates Overweight on...
09/03/2024 14:03:37

Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.

RBC Capital Maintains Outperform on Perspe...
08/16/2024 16:06:42

RBC Capital analyst Gregory Renza maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price targ...

Oppenheimer Maintains Outperform on Perspe...
08/13/2024 12:17:53

Oppenheimer analyst Jeff Jones maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target ...

UPDATE: Perspective Therapeutics Q2 EPS $(...
08/12/2024 20:23:09

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate o...

B of A Securities Initiates Coverage On Pe...
07/25/2024 11:44:15

B of A Securities analyst Alec Stranahan initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and an...

Cantor Fitzgerald Reiterates Overweight on...
06/25/2024 14:55:16

Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:29:33

Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.

Oppenheimer Reiterates Outperform on Persp...
06/18/2024 15:02:01

Oppenheimer analyst Jeff Jones reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform, Adjusts Target to $19 from $...

Oppenheimer Reiterates Outperform on Persp...
06/18/2024 14:32:37

Oppenheimer analyst Jeff Jones reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform, Adjusts Target to $19 from $2...

Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 14:00:42

Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.

RBC Capital Reiterates Outperform on Persp...
06/14/2024 14:00:49

RBC Capital analyst Gregory Renza reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $3 price t...

18m-bet-on-this-health-care-stock-check-out-these-3-penny-stocks-insiders-are-aggressively-buying

$1.8M Bet On This Health Care Stock? Check...
06/14/2024 11:15:34

Perspective Therapeutics Announces 1-For-1...
06/11/2024 11:01:55

Perspective Therapeutics Announces Six Upd...
06/10/2024 20:11:54

expensify-and-2-other-stocks-under-2-insiders-are-buying

Expensify And 2 Other Stocks Under $2 Insi...
06/04/2024 11:24:05

Perspective Therapeutics Prices $80M Under...
05/24/2024 12:03:51

Jones Trading Maintains Buy on Perspective...
05/16/2024 16:28:06

Jones Trading analyst Justin Walsh maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target fro...

Perspective Therapeutics Q1 2024 GAAP EPS ...
05/15/2024 11:04:08